Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition
Mehri Monavarian, Resha Rajkarnikar, Emily Faith Page, Asha Kumari, Liz Quintero Macias, Felipe Massicano, Nam Y. Lee, Sarthak Sahoo, Nadine Hempel, Mohit Kumar Jolly, Lara Ianov, Elizabeth Worthey, Abhyudai Singh, Igor B. Roninson, Eugenia V. Broude, Mengqian Chen, Karthikeyan Mythreye
Mehri Monavarian, Resha Rajkarnikar, Emily Faith Page, Asha Kumari, Liz Quintero Macias, Felipe Massicano, Nam Y. Lee, Sarthak Sahoo, Nadine Hempel, Mohit Kumar Jolly, Lara Ianov, Elizabeth Worthey, Abhyudai Singh, Igor B. Roninson, Eugenia V. Broude, Mengqian Chen, Karthikeyan Mythreye
View: Text | PDF
Research Article Cell biology Oncology

Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition

  • Text
  • PDF
Abstract

Anoikis resistance, or evasion of cell death triggered by matrix detachment, is a hallmark of cancer cell survival and metastasis. We showed that repeated exposure to suspension stress followed by recovery under attached conditions leads to development of anoikis resistance. The acquisition of anoikis resistance was associated with enhanced invasion, chemoresistance, and immune evasion in vitro and distant metastasis in vivo. This acquired anoikis resistance was not genetic, persisting for a finite duration without detachment stress, but was sensitive to CDK8/19 mediator kinase inhibition that could also reverse anoikis resistance. Transcriptomic analysis revealed that CDK8/19 kinase inhibition induces bidirectional transcriptional changes in both sensitive and resistant cells, disrupting the balanced reprogramming required for anoikis adaptation and resistance by reversing some resistance-associated pathways and enhancing others. Both anoikis resistance and in vivo metastatic growth of ovarian cancers are sensitive to CDK8/19 inhibition, thereby providing a therapeutic opportunity to both prevent and suppress ovarian cancer metastasis.

Authors

Mehri Monavarian, Resha Rajkarnikar, Emily Faith Page, Asha Kumari, Liz Quintero Macias, Felipe Massicano, Nam Y. Lee, Sarthak Sahoo, Nadine Hempel, Mohit Kumar Jolly, Lara Ianov, Elizabeth Worthey, Abhyudai Singh, Igor B. Roninson, Eugenia V. Broude, Mengqian Chen, Karthikeyan Mythreye

×

Figure 1

Development of anoikis resistance upon cyclic exposure to matrix detachment stress.

Options: View larger image (or click on image) Download as PowerPoint
Development of anoikis resistance upon cyclic exposure to matrix detachm...
(A) Percent live cells after 24 hours in suspension (trypan blue exclusion). n ≥ 3 per cell line. (B) Schematic of cyclic attached growth and suspension culture. (C) Percent live cells in suspension for indicated AnS cells following cyclic attachment-detachment as in B. (n = 3–12 per cell line.) (D) Doubling time of OV90 parental (AnS) and AnR (P7–P9) cells in attached (7 days) or suspension (10 days) culture. (E) Ki67 (red) normalized to DAPI in OV90 AnS and AnR cells after 24 hours in suspension. n = 3 with each trial including quantitation of at least 4 original magnification, 20×, fields. (F) Live/dead staining (Calcein AM green, live cells and ethidium homodimer; red, dead cells) of AnS and AnR cells after 24 hours in suspension (ULA plates); n = 6. (G) Representative images of cleaved caspase-3 Western blot in AnS and AnR cells after 24 hours in suspension; quantitation of cleaved caspase-3 normalized to β-actin shown below (n = 2). (H) Annexin V/PI flow cytometry (left) and quantitation (right) in AnS and AnR cells after 24 hours in suspension; n = 3. (I) Percent live cells in suspension of in vitro–derived (AnS/AnR) and mouse ascites-derived (at endpoint) OV90 and ID8 cells; n = 2–5. Scale bars: 100 μm (E), 200 μm (F). Data are mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 by 2-tailed unpaired t test (D and E) or 1-way ANOVA with Tukey’s test (F, H, and I).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts